Fundraising Fox
General Fluidics
Waltham, US · Delaware corporation · 1 known investors
Find your way into General Fluidics
Sign up to see every warm intro you have to General Fluidics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the General Fluidics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
General Fluidics builds Axess, a point-of-care diagnostic analyzer powered by its patented Embedded Fluidics Systems that runs clinical chemistry, hematology, and immunoassay panels from a single cartridge in under 20 minutes. It targets decentralized healthcare settings such as doctors' offices and clinics, enabling reference-lab-quality blood test results during a single patient visit.
Founders & leadership
RW
Robert WarrenChief Operating Officer2021–2025Robert Warren is a managing director at Lake Street Capital Markets with a background in corporate law, venture capital, and healthcare operations. Previously, he served as Chief Operating Officer and Chief Financial Officer at General Fluidics, a diagnostic company, and at AZTherapies, a biopharmaceutical firm developing Alzheimer's treatments, and spent nearly 12 years as a corporate attorney at Foley Hoag LLP specializing in life sciences transactions.
JN
Jason NapolitanoNamed on SEC filing
RT
Ronald TompkinsNamed on SEC filing
Board
MG
Marc GoldbergBoard director
TH
Timothy HirschBoard director
NG
Nancy GaglianoBoard director
RH
Ramin HaghgooieBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$34.6M disclosed across 4 rounds · 2018–2024
▶$18.5MraisedJul 2024 · 16 investors · Other Health CareRule 506(b)
▶$18.5MraisedJul 2024 · 16 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Timothy HirschDirector
- Robert GranierExecutive Officer, Director
- Marc GoldbergDirector
- Robert WarrenExecutive Officer
- Nancy GaglianoDirector
- Ramin HaghgooieDirector
- Offering amount
- $27.9M
- Amount sold
- $18.5M
- Placement agents
- Wingate Asset Management Limited
- First sale
- Jul 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.1MraisedJun 2023 · 10 investors · Other Health CareRule 506(b)
▶$4.1MraisedJun 2023 · 10 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Christopher SveenDirector
- Ramin HaghgooieDirector
- Nancy GaglianoDirector
- Robert WarrenExecutive Officer
- Keith GreenfieldDirector
- Robert GranierExecutive Officer, Director
- Offering amount
- $8.3M
- Amount sold
- $4.1M
- First sale
- Jun 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6.7MraisedDec 2020 · 1 investors · Other Health CareRule 506(b)
▶$6.7MraisedDec 2020 · 1 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- RONALD TOMPKINSDirector
- CHRISTOPHER SVEENDirector
- ROBERT GRANIERExecutive Officer, Director
- KEITH GREENFIELDDirector
- Offering amount
- $6.7M
- Amount sold
- $6.7M
- First sale
- Dec 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.4MraisedOct 2018 · 2 investors · Other Health CareRule 506(b)
▶$5.4MraisedOct 2018 · 2 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Jason NapolitanoDirector
- Ronald TompkinsDirector
- Robert GranierExecutive Officer, Director
- Offering amount
- $5.4M
- Amount sold
- $5.4M
- First sale
- Sep 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 3
Macrogenics IncMacroGenics is a clinical-stage biopharmaceutical company developing antibody-based therapies for cancer patients. It advances a pipeline of product candidates using proprietary platforms for antibody-drug conjugates, bispecific checkpoint antibodies, and T-cell engagers.
CenegenicsCenegenics is a physician-led age management and performance health system that uses diagnostics and data-driven interventions to help individuals optimize strength, cognition, metabolic health, and longevity. The company serves individuals seeking personalized, medically grounded approaches to extending peak physical and cognitive performance.
PhigenicsPhigenics provides water management and Legionella prevention solutions for healthcare and institutional facilities. The company has over 20 years of experience helping organizations ensure water safety and regulatory compliance.
Companies working in the same space as General Fluidics.
Frequently asked questions
- What does General Fluidics do?
- General Fluidics builds Axess, a point-of-care diagnostic analyzer powered by its patented Embedded Fluidics Systems that runs clinical chemistry, hematology, and immunoassay panels from a single cartridge in under 20 minutes. It targets decentralized healthcare settings such as doctors' offices and clinics, enabling reference-lab-quality blood test results during a single patient visit.
- Who are General Fluidics's investors?
- General Fluidics's investors include Kendall Capital Partners.
- How much funding has General Fluidics raised?
- General Fluidics has disclosed $34.6M raised across 4 rounds.
- Where is General Fluidics headquartered?
- General Fluidics is headquartered in Waltham, US.